WEST PHARMACEUTICAL SERVICES (WST) Fundamental Analysis & Valuation

NYSE:WST • US9553061055

Current stock price

278 USD
+4.27 (+1.56%)
At close:
278 USD
0 (0%)
After Hours:

This WST fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. WST Profitability Analysis

1.1 Basic Checks

  • In the past year WST was profitable.
  • In the past year WST had a positive cash flow from operations.
  • WST had positive earnings in each of the past 5 years.
  • WST had a positive operating cash flow in each of the past 5 years.
WST Yearly Net Income VS EBIT VS OCF VS FCFWST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

1.2 Ratios

  • The Return On Assets of WST (11.56%) is better than 92.86% of its industry peers.
  • WST has a Return On Equity of 15.54%. This is amongst the best in the industry. WST outperforms 91.07% of its industry peers.
  • With an excellent Return On Invested Capital value of 14.09%, WST belongs to the best of the industry, outperforming 94.64% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for WST is above the industry average of 11.80%.
Industry RankSector Rank
ROA 11.56%
ROE 15.54%
ROIC 14.09%
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
WST Yearly ROA, ROE, ROICWST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • WST's Profit Margin of 16.06% is amongst the best of the industry. WST outperforms 85.71% of its industry peers.
  • WST's Profit Margin has been stable in the last couple of years.
  • Looking at the Operating Margin, with a value of 20.53%, WST belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
  • In the last couple of years the Operating Margin of WST has remained more or less at the same level.
  • The Gross Margin of WST (35.91%) is worse than 60.71% of its industry peers.
  • In the last couple of years the Gross Margin of WST has remained more or less at the same level.
Industry RankSector Rank
OM 20.53%
PM (TTM) 16.06%
GM 35.91%
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
WST Yearly Profit, Operating, Gross MarginsWST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. WST Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so WST is still creating some value.
  • The number of shares outstanding for WST has been reduced compared to 1 year ago.
  • The number of shares outstanding for WST has been reduced compared to 5 years ago.
  • The debt/assets ratio for WST has been reduced compared to a year ago.
WST Yearly Shares OutstandingWST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
WST Yearly Total Debt VS Total AssetsWST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • WST has an Altman-Z score of 14.00. This indicates that WST is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 14.00, WST belongs to the best of the industry, outperforming 98.21% of the companies in the same industry.
  • WST has a debt to FCF ratio of 0.44. This is a very positive value and a sign of high solvency as it would only need 0.44 years to pay back of all of its debts.
  • WST has a better Debt to FCF ratio (0.44) than 92.86% of its industry peers.
  • WST has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of WST (0.06) is better than 67.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.44
Altman-Z 14
ROIC/WACC1.28
WACC11%
WST Yearly LT Debt VS Equity VS FCFWST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 3.02 indicates that WST has no problem at all paying its short term obligations.
  • WST's Current ratio of 3.02 is in line compared to the rest of the industry. WST outperforms 57.14% of its industry peers.
  • WST has a Quick Ratio of 2.34. This indicates that WST is financially healthy and has no problem in meeting its short term obligations.
  • WST has a Quick ratio of 2.34. This is comparable to the rest of the industry: WST outperforms 55.36% of its industry peers.
Industry RankSector Rank
Current Ratio 3.02
Quick Ratio 2.34
WST Yearly Current Assets VS Current LiabilitesWST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. WST Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 8.00% over the past year.
  • The Earnings Per Share has been growing by 8.94% on average over the past years. This is quite good.
  • Looking at the last year, WST shows a small growth in Revenue. The Revenue has grown by 6.25% in the last year.
  • The Revenue has been growing slightly by 7.44% on average over the past years.
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%7.51%

3.2 Future

  • Based on estimates for the next years, WST will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.50% on average per year.
  • WST is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.60% yearly.
EPS Next Y11.24%
EPS Next 2Y11.04%
EPS Next 3Y11.52%
EPS Next 5Y9.5%
Revenue Next Year6.04%
Revenue Next 2Y6.13%
Revenue Next 3Y6.47%
Revenue Next 5Y5.6%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
WST Yearly Revenue VS EstimatesWST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
WST Yearly EPS VS EstimatesWST Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

4

4. WST Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 38.13 indicates a quite expensive valuation of WST.
  • WST's Price/Earnings ratio is a bit cheaper when compared to the industry. WST is cheaper than 64.29% of the companies in the same industry.
  • WST is valuated rather expensively when we compare the Price/Earnings ratio to 27.95, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 34.28, the valuation of WST can be described as expensive.
  • 64.29% of the companies in the same industry are more expensive than WST, based on the Price/Forward Earnings ratio.
  • WST is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 38.68, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 38.13
Fwd PE 34.28
WST Price Earnings VS Forward Price EarningsWST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • 64.29% of the companies in the same industry are more expensive than WST, based on the Enterprise Value to EBITDA ratio.
  • WST's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. WST is cheaper than 60.71% of the companies in the same industry.
Industry RankSector Rank
P/FCF 42.73
EV/EBITDA 24.25
WST Per share dataWST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates WST does not grow enough to justify the current Price/Earnings ratio.
  • WST has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)3.39
PEG (5Y)4.26
EPS Next 2Y11.04%
EPS Next 3Y11.52%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. WST Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.33%, WST is not a good candidate for dividend investing.
  • WST's Dividend Yield is rather good when compared to the industry average which is at 0.11. WST pays more dividend than 83.93% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.81, WST's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.33%

5.2 History

  • The dividend of WST has a limited annual growth rate of 5.48%.
  • WST has been paying a dividend for at least 10 years, so it has a reliable track record.
  • WST has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)5.48%
Div Incr Years33
Div Non Decr Years34
WST Yearly Dividends per shareWST Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • WST pays out 12.40% of its income as dividend. This is a sustainable payout ratio.
  • The dividend of WST is growing, but earnings are growing more, so the dividend growth is sustainable.
DP12.4%
EPS Next 2Y11.04%
EPS Next 3Y11.52%
WST Yearly Income VS Free CF VS DividendWST Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
WST Dividend Payout.WST Dividend Payout, showing the Payout Ratio.WST Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

WST Fundamentals: All Metrics, Ratios and Statistics

WEST PHARMACEUTICAL SERVICES

NYSE:WST (4/20/2026, 8:04:00 PM)

After market: 278 0 (0%)

278

+4.27 (+1.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12
Earnings (Next)04-23
Inst Owners97.62%
Inst Owner Change-0.26%
Ins Owners0.29%
Ins Owner Change0.38%
Market Cap20.04B
Revenue(TTM)3.07B
Net Income(TTM)493.70M
Analysts80.87
Price Target328.99 (18.34%)
Short Float %4.08%
Short Ratio3.06
Dividend
Industry RankSector Rank
Dividend Yield 0.33%
Yearly Dividend0.85
Dividend Growth(5Y)5.48%
DP12.4%
Div Incr Years33
Div Non Decr Years34
Ex-Date04-29
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.82%
Min EPS beat(2)10.24%
Max EPS beat(2)15.4%
EPS beat(4)4
Avg EPS beat(4)15.68%
Min EPS beat(4)10.24%
Max EPS beat(4)20.68%
EPS beat(8)7
Avg EPS beat(8)12.16%
EPS beat(12)11
Avg EPS beat(12)11.7%
EPS beat(16)14
Avg EPS beat(16)11.27%
Revenue beat(2)2
Avg Revenue beat(2)0.72%
Min Revenue beat(2)0.33%
Max Revenue beat(2)1.1%
Revenue beat(4)4
Avg Revenue beat(4)1.63%
Min Revenue beat(4)0.33%
Max Revenue beat(4)4.33%
Revenue beat(8)7
Avg Revenue beat(8)1.11%
Revenue beat(12)8
Avg Revenue beat(12)0.49%
Revenue beat(16)10
Avg Revenue beat(16)0.34%
PT rev (1m)0%
PT rev (3m)-7.08%
EPS NQ rev (1m)-0.05%
EPS NQ rev (3m)1.65%
EPS NY rev (1m)0.09%
EPS NY rev (3m)3.31%
Revenue NQ rev (1m)0.15%
Revenue NQ rev (3m)2.55%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.21%
Valuation
Industry RankSector Rank
PE 38.13
Fwd PE 34.28
P/S 6.52
P/FCF 42.73
P/OCF 26.55
P/B 6.31
P/tB 6.55
EV/EBITDA 24.25
EPS(TTM)7.29
EY2.62%
EPS(NY)8.11
Fwd EY2.92%
FCF(TTM)6.51
FCFY2.34%
OCF(TTM)10.47
OCFY3.77%
SpS42.65
BVpS44.06
TBVpS42.43
PEG (NY)3.39
PEG (5Y)4.26
Graham Number85.0135 (-69.42%)
Profitability
Industry RankSector Rank
ROA 11.56%
ROE 15.54%
ROCE 17.45%
ROIC 14.09%
ROICexc 18.03%
ROICexgc 18.82%
OM 20.53%
PM (TTM) 16.06%
GM 35.91%
FCFM 15.25%
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
ROICexc(3y)20.32%
ROICexc(5y)23.97%
ROICexgc(3y)21.34%
ROICexgc(5y)25.37%
ROCE(3y)19.61%
ROCE(5y)22.21%
ROICexgc growth 3Y-13.74%
ROICexgc growth 5Y-3.06%
ROICexc growth 3Y-13.28%
ROICexc growth 5Y-2.17%
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
F-Score7
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.44
Debt/EBITDA 0.26
Cap/Depr 166.8%
Cap/Sales 9.3%
Interest Coverage 2103.33
Cash Conversion 94.07%
Profit Quality 94.98%
Current Ratio 3.02
Quick Ratio 2.34
Altman-Z 14
F-Score7
WACC11%
ROIC/WACC1.28
Cap/Depr(3y)224.35%
Cap/Depr(5y)223.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)10.68%
Profit Quality(3y)73.64%
Profit Quality(5y)69.18%
High Growth Momentum
Growth
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
EPS Next Y11.24%
EPS Next 2Y11.04%
EPS Next 3Y11.52%
EPS Next 5Y9.5%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%7.51%
Revenue Next Year6.04%
Revenue Next 2Y6.13%
Revenue Next 3Y6.47%
Revenue Next 5Y5.6%
EBIT growth 1Y7.88%
EBIT growth 3Y-5.8%
EBIT growth 5Y8.6%
EBIT Next Year43.62%
EBIT Next 3Y20.28%
EBIT Next 5Y13.54%
FCF growth 1Y69.65%
FCF growth 3Y2.19%
FCF growth 5Y9.48%
OCF growth 1Y15.52%
OCF growth 3Y1.4%
OCF growth 5Y9.82%

WEST PHARMACEUTICAL SERVICES / WST Fundamental Analysis FAQ

What is the fundamental rating for WST stock?

ChartMill assigns a fundamental rating of 6 / 10 to WST.


What is the valuation status for WST stock?

ChartMill assigns a valuation rating of 4 / 10 to WEST PHARMACEUTICAL SERVICES (WST). This can be considered as Fairly Valued.


How profitable is WEST PHARMACEUTICAL SERVICES (WST) stock?

WEST PHARMACEUTICAL SERVICES (WST) has a profitability rating of 7 / 10.


What is the financial health of WEST PHARMACEUTICAL SERVICES (WST) stock?

The financial health rating of WEST PHARMACEUTICAL SERVICES (WST) is 8 / 10.


What is the expected EPS growth for WEST PHARMACEUTICAL SERVICES (WST) stock?

The Earnings per Share (EPS) of WEST PHARMACEUTICAL SERVICES (WST) is expected to grow by 11.24% in the next year.